Alternative splicing of RNA is an essential mechanism that increases proteomic diversity in eukaryotic cells. Aberrant alternative splicing is often associated with various human diseases, including cancer. We conducted whole-transcriptome analysis of 18 osteosarcoma bone samples (paired normal—tumor biopsies). Using RNA-seq, we identified statistically significant (FDR <0.05) 26 differentially expressed transcript variants of leptin receptor overlapping transcript (LEPROT) gene. Some of the transcripts were overexpressed in normal cells, whereas others were overexpressed in tumor cells. The function of LEPROT is not completely understood. Herein, we highlight a possible association between OS and aberrant alternative splicing events and its interaction with the expression of LEPROT. We also discuss the role of LEPROT in regulating growth hormone and its receptor, and the relationship with initiation and progression of OS. This research study may help to understand the association of alternative splicing mechanism in OS and in tumorigenesis more generally. Further, LEPROT gene can also be considered as a potential biomarker of osteosarcoma.
Impact statement
Osteosarcoma (OS, also known as osteogenic sarcoma) is the most common primary malignancy of bone in children and adolescents. The molecular mechanisms of OS are extremely complicated and its molecular mediators remain to be elucidated. We sequenced total RNA from 18 OS bone samples (paired normal—tumor biopsies). We found statistically significant (FDR <0.05) 26 differentially expressed transcript variants of LEPROT gene with different expressions in normal and tumor samples. These findings contribute to the understanding of molecular mechanisms of OS development and provide encouragement to pursue further research.
MirabelloLTroisiRJSavageSA.Osteosarcoma incidence and survival rates from 1973 to 2004: data from the surveillance, epidemiology, and end results program. Cancer2009;
115:1531–43
2.
DurfeeRAMohammedMLuuHH.Review of osteosarcoma and current management. Rheumatol Ther2016;
3:221–43
3.
BrownHKSchiavoneKGouinFHeymannMFHeymannD.Biology of bone sarcomas and new therapeutic developments. Calcif Tissue Int2018;
102:174–95
4.
XuQGaoTZhangBZengJDaiM.Primary osteosarcoma in elderly patients: a report of three cases. Oncol Lett2019;
18:990–6
5.
ZhangXGuanZ.PET/CT in the diagnosis and prognosis of osteosarcoma. Front Biosci2018;
23:2157–65
6.
WaghAKokaneGJendiSKhatibSMistryJVaidyaK.Early diagnosis: a seeming misfortune for osteosarcoma of mandible-rare case report. Indian J Otolaryngol Head Neck Surg2019;
71:748–51
7.
YangPGilgMEvansSTottiFStevensonJJeysLParryM.Survival of osteosarcoma patients following diagnosis of synchronous skip metastases. J Orthop2020;
18:121–5
8.
IgarashiKYamamotoNShiraiTNishidaHHayashiKTanzawaYKimuraHTakeuchiAMiwaSInataniHShimozakiSKatoTTsuchiyaH.Late recurrence of osteosarcoma: a report of two cases. J Orthop Surg2014;
22:415–9
9.
Pritchard-JonesKKaatschPSteliarova-FoucherEStillerCACoeberghJW.Cancer in children and adolescents in Europe: developments over 20 years and future challenges. Eur J Cancer2006;
42:2183–90
SetonM.Paget disease of bone: diagnosis and drug therapy. Cleve Clin J Med2013;
80:452–62
12.
SrivastavaSWangSTongYAPirolloKChangEH.Several mutant p53 proteins detected in cancer-prone families with Li-Fraumeni syndrome exhibit transdominant effects on the biochemical properties of the wild-type p53. Oncogene1993;
8:2449–56
13.
HansenMFKoufosAGallieBLPhillipsRAFodstadOBroggerAGedde-DahlTCaveneeWK.Osteosarcoma and retinoblastoma: a shared chromosomal mechanism revealing recessive predisposition. Proc Natl Acad Sci U S A1985;
82:6216–20
14.
WangZGersteinMSnyderM.RNA-Seq: a revolutionary tool for transcriptomics. Nat Rev Genet2009;
10:57–63
15.
KukurbaKRMontgomerySB.RNA sequencing and analysis. Cold Spring Harb Protoc2015;
2015:951–69
16.
ButzHPatocsA.Brief summary of the most important molecular genetic methods (PCR, qPCR, microarray, Next-Generation sequencing, etc.). Exp Suppl2019;
111:33–52
LiYRaoXMattoxWWAmosCILiuB.RNA-Seq analysis of differential splice junction usage and intron retentions by DEXSeq. PLoS One2015;
10:e0136653
19.
El MarabtiEYounisI.The cancer spliceome: reprograming of alternative splicing in cancer. Front Mol Biosci2018;
5:80
20.
FrostFGCherukuriPFMilanovichSBoerkoelCF.Pan-cancer RNA-seq data stratifies tumours by some hallmarks of cancer. J Cell Mol Med2020;
24:418–30
21.
SrebrowAKornblihttAR.The connection between splicing and cancer. J Cell Sci2006;
119:2635–41
22.
EksiRLiHDMenonRWenYOmennGSKretzlerMGuanY.Systematically differentiating functions for alternatively spliced isoforms through integrating RNA-seq data. PLoS Comput Biol2013;
9:e1003314
23.
GhignaCValaccaCBiamontiG.Alternative splicing and tumor progression. Curr Genomics2008;
9:556–70
24.
YangQZhaoJZhangWChenDWangY.Aberrant alternative splicing in breast cancer. J Mol Cell Biol2019;
11:920–9
25.
VenablesJP.Aberrant and alternative splicing in cancer. Cancer Res2004;
64:7647–54
26.
WangYLiuJHuangBOXuYMLiJHuangLFLinJZhangJMinQHYangWMWangXZ.Mechanism of alternative splicing and its regulation. Biomed Rep2015;
3:152–8
27.
SveenAKilpinenSRuusulehtoALotheRASkotheimRI.Aberrant RNA splicing in cancer; expression changes and driver mutations of splicing factor genes. Oncogene2016;
35:2413–27
28.
QiFLiYYangXWuYPLinLJLiuXM.Significance of alternative splicing in cancer cells. Chin Med J2020;
133:221–8
29.
DvingeHGuenthoerJPorterPLBradleyRK.RNA components of the spliceosome regulate tissue- and cancer-specific alternative splicing. Genome Res2019;
29:1591–604
30.
HoXDPhungPVQLVHNReimannEPransEKoksGMaasaluKLeNTLHTHGNMartsonAKoksS.Whole transcriptome analysis identifies differentially regulated networks between osteosarcoma and normal bone samples. Exp Biol Med2017;
242:1802–11
31.
AndersSReyesAHuberW.Detecting differential usage of exons from RNA-seq data. Genome Res2012;
22:2008–17
32.
HoXDNguyenHGTrinhLHReimannEPransEKoksGMaasaluKLeVQNguyenVHLeNTNPhungPMartsonALattekiviFKoksS.Analysis of the expression of repetitive DNA elements in osteosarcoma. Front Genet2017;
8:193
33.
McCarthyDJChenYSmythGK.Differential expression analysis of multifactor RNA-Seq experiments with respect to biological variation. Nucleic Acids Res2012;
40:4288–97
34.
LiJWittenDMJohnstoneIMTibshiraniR.Normalization, testing, and false discovery rate estimation for RNA-sequencing data. Biostatistics2012;
13:523–38
35.
AndersSMcCarthyDJChenYOkoniewskiMSmythGKHuberWRobinsonMD.Count-based differential expression analysis of RNA sequencing data using R and bioconductor. Nat Protoc2013;
8:1765–86
36.
BenjaminiYH.Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc1995;
57:289–300
37.
Dey-RaoRSeiffert-SinhaKSinhaAA.Genome-wide expression analysis suggests unique disease-promoting and disease-preventing signatures in pemphigus vulgaris. Genes Immun2013;
14:487–99
38.
BoiseLHGonzalez-GarciaMPostemaCEDingLLindstenTTurkaLAMaoXNunezGThompsonCB.Bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell1993;
74:597–608
39.
NarrandesSHuangSMurphyLXuW.The exploration of contrasting pathways in triple negative breast cancer (TNBC). BMC Cancer2018;
18:22
40.
WongACHRaskoJEJWongJJ.We skip to work: alternative splicing in normal and malignant myelopoiesis. Leukemia2018;
32:1081–93
41.
HugNLongmanDCaceresJF.Mechanism and regulation of the nonsense-mediated decay pathway. Nucleic Acids Res2016;
44:1483–95
42.
HeFJacobsonA.Nonsense-Mediated mRNA decay: degradation of defective transcripts is only part of the story. Annu Rev Genet2015;
49:339–66
43.
PoppMWMaquatLE.Nonsense-mediated mRNA decay and cancer. Curr Opin Genet Dev2018;
48:44–50
44.
YousefiMKarmausWZhangHEwartSArshadHHollowayJW.The methylation of the LEPR/LEPROT genotype at the promoter and body regions influence concentrations of leptin in girls and BMI at age 18 years if their mother smoked during pregnancy. Int J Mol Epidemiol Genet2013;
4:86–100
45.
InzucchiSERobbinsRJ.Clinical review 61: effects of growth hormone on human bone biology. J Clin Endocrinol Metab1994;
79:691–4
46.
ChiaDJ.Minireview: mechanisms of growth hormone-mediated gene regulation. Mol Endocrinol2014;
28:1012–25
47.
WuSYangWDe LucaF.Insulin-Like growth Factor-Independent effects of growth hormone on growth plate chondrogenesis and longitudinal bone growth. Endocrinology2015;
156:2541–51
48.
TuzcuSDurmazSACarliogluADemircanZTuzcuABeyazCTayA.The effects of high serum growth hormone and IGF-1 levels on bone mineral density in acromegaly. Z Rheumatol2017;
76:716–22
49.
ChengMHuangWCaiWFangMChenYWangCYanW.Growth hormone receptor promotes osteosarcoma cell growth and metastases. FEBS Open Bio2020;
10:127–34
50.
ZhuTGohELGraichenRLingLLobiePE.Signal transduction via the growth hormone receptor. Cell Signal2001;
13:599–616
51.
KopchickJJAndryJM.Growth hormone (GH), GH receptor, and signal transduction. Mol Genet Metab2000;
71:293–314
52.
Banziger-ToblerNEHalinCKajiyaKDetmarM.Growth hormone promotes lymphangiogenesis. Am J Pathol2008;
173:586–97
53.
LiYSLiuQHeHBLuoW.The possible role of insulin-like growth factor-1 in osteosarcoma. Curr Probl Cancer2019;
43:228–35
54.
NairPNDe ArmondDTAdamoMLStrodelWEFreemanJW.Aberrant expression and activation of insulin-like growth factor-1 receptor (IGF-1R) are mediated by an induction of IGF-1R promoter activity and stabilization of IGF-1R mRNA and contributes to growth factor independence and increased survival of the pancreatic cancer cell line MIA PaCa-2. Oncogene2001;
20:8203–14
55.
TouvierTConte-AuriolFBriandOCudejkoCPaumelleRCaronSBaugeERouilleYSallesJPStaelsBBailleulB.LEPROT and LEPROTL1 cooperatively decrease hepatic growth hormone action in mice. J Clin Invest2009;
119:3830–8
56.
JinHJinXCaoBWangW.Berberine affects osteosarcoma via downregulating the caspase-1/IL-1beta signaling axis. Oncol Rep2017;
37:729–36
57.
MoriTSatoYMiyamotoKKobayashiTShimizuTKanagawaHKatsuyamaEFujieAHaoWTandoTIwasakiRKawanaHMoriokaHMatsumotoMSayaHToyamaYMiyamotoT.TNFalpha promotes osteosarcoma progression by maintaining tumor cells in an undifferentiated state. Oncogene2014;
33:4236–41
58.
WuZYangWLiuJZhangF.Interleukin-6 upregulates SOX18 expression in osteosarcoma. Onco Targets Ther2017;
10:5329–36
59.
RoblBBotterSMBoroAMeierDNeriDFuchsB.Evaluation of F8-TNF-alpha in models of early and progressive metastatic osteosarcoma. Transl Oncol2017;
10:419–30
60.
ItohHKadomatsuTTanoueHYugamiMMiyataKEndoMMorinagaJKobayashiEMiyamotoTKurahashiRTeradaKMizutaHOikeY.TET2-dependent IL-6 induction mediated by the tumor microenvironment promotes tumor metastasis in osteosarcoma. Oncogene2018;
37:2903–20
61.
ZhangCMaKLiWY.IL-6 promotes cancer stemness and oncogenicity in U2OS and MG-63 osteosarcoma cells by upregulating the OPN-STAT3 pathway. J Cancer2019;
10:6511–25
